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Summary
Sickle cell disease (SCD) is associated with vascular complications including
premature stroke. The role of atherothrombosis in these vascular
complications is unclear. To determine the effect of SCD on atherosclerosis
and thrombosis, mice with SCD along with controls were generated by trans-
plantation of bone marrow from mice carrying the homozygous sickle cell
mutation (Hbbhbs/hbs) or wild-type mice (Hbb+/+) into C57BL6/J or apoli-
poprotein E deficient (Apoe/) recipient mice. At the time of sacrifice,
23–28 weeks following bone marrow transplantation, anaemia, reticulocy-
tosis, and splenomegaly were present in mice receiving Hbbhbs/hbs bone
marrow compared with control mice. Analysis of atherosclerosis involving
the aortic root revealed reduced atherosclerotic lesion area with reduced
macrophage content and increased collagen content in Apoe/, Hbbhbs/hbs
mice compared to Apoe/, Hbb+/+ mice. In a carotid thrombosis model, the
time to thrombosis was prolonged in Hbbhbs/hbs mice compared to Hbb+/+
mice. This apparent protective effect of SCD on atherosclerosis and throm-
bosis was diminished by inhibition of heme oxygenase-1 (HMOX1) using
zinc protoporphyrin IX.
We conclude that SCD in mice is paradoxically protective against
atherosclerosis and thrombosis, highlighting the complexity of vascular events
in SCD. This protective effect is at least partially mediated by induction of
HMOX1.
Keywords: atherosclerosis, bone marrow transplant, haem oxygenase,
thrombosis.
Sickle cell disease (SCD) is a haemoglobinopathy caused by
a missense mutation in the beta globin gene, predisposing
haemoglobin to abnormal polymerization in response to
stressors (Rees et al, 2010). This change in haemoglobin
polymerization leads to stiff red blood cells that form
aggregates, often resulting in impairment of microcirculato-
ry flow, tissue ischaemia, and infarction. While SCD is
generally associated with a proinflammatory state, protective
mechanisms have also been shown to be activated in SCD
that may lessen the severity of disease complications (Rees
et al, 2010). Some patients experience stroke at an early
age, although the underlying mechanisms are not fully
understood (Adams et al, 1997; Morris, 2011). Myocardical
infarction (MI) has been reported although the true inci-
dence is unclear. In one review of 108 patients with SCD,
MI occurred in 27% of patients (Barrett et al, 1984).
However, the diagnosis is often missed and made only at
autopsy (Barrett et al, 1984; Martin et al, 1996). The effect
of SCD on atherosclerosis, the underlying substrate for
most MI and stroke, is also unclear because of small study
populations. However, some studies have demonstrated
normal coronary arteries in SCD patients with MI, suggest-
ing underlying atherosclerosis is not the culprit (Gerry et al,
1978; McCormick, 1988; Mansi & Rosner, 2002). Given that
vascular changes similar to premature atherosclerosis and/or
thrombophilia could contribute to stroke in SCD, we stud-
ied the effect of sickle cell anaemia on the progression of
atherosclerosis and on arterial thrombosis in a mouse
model of SCD. To study atherosclerosis, we used the ath-
erosclerotic-prone apolipoprotein E deficient mouse model
because these mice develop hyperlipidaemia and accelerated
atherosclerosis (Plump et al, 1992; Nakashima et al, 1994).
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Methods
Animals
Male apolipoprotein E deficient (Apoe/) and C57BL6/J
(wild-type, WT) mice were purchased from Jackson Labora-
tory (Bar Harbor, Maine, USA). Donor mice carrying homo-
zygous sickle cell mutation (Hbbhbs/hbs) were originally from
University of Alabama at Birmingham and these mice have
subsequently been bred to C57BL6/J mice to generate hetero-
zygous mice, which were then intercrossed to produce the
homozygous Hbbhbs/hbs donors (Campbell et al, 2011). SCD
and control experimental mice were then generated by bone
marrow transplantation (BMT) from Hbbhbs/hbs mice or
wild-type (Hbb+/+) donors to wild-type or Apoe/ recipi-
ents. Mice were housed under specific pathogen-free condi-
tions in static microisolator cages with tap water ad libitum
in a temperature-controlled room with a 12:12-h light/dark
cycle. The bone marrow chimeric mice with Apoe/ back-
ground were fed a Western diet (TD88137, Harlan, WI,
USA) following BMT. Bone marrow chimeras with Apoe+/+
background were fed a standard laboratory rodent diet
(No. 5001, TestDiet, Richmond, IN, USA). All animal use
protocols complied with the Principle of Laboratory and
Animal Care established by the National Society for Medical
Research and were approved by the University of Michigan
Committee on Use and Care of Animals.
Bone marrow transplantation
At 8 weeks of age, WT or Apoe/ mice were irradiated and
BMT was performed as previously described (Bodary et al,
2002). Each recipient mouse was irradiated (2 9 650 rad
[002 9 65 Gy]) and injected with 4 9 106 bone marrow
cells via the tail vein. For atherosclerosis studies, Apoe/
mice were used as recipients for Hbb+/+ and Hbbhbs/hbs donor
marrow, and they were fed a Western diet for 14 weeks
beginning at 6 weeks following the BMT, after which mice
were euthanized. For thrombosis studies, WT mice were used
as recipients for Hbb+/+ and Hbbhbs/hbs donor marrow, and
they were fed a standard diet for 23 weeks following BMT,
after which they were euthanized.
Haemoglobin analysis
Blood haemoglobin content was determined by high-perfor-
mance liquid chromatography (HPLC) 10 weeks after BMT
as previously described (Campbell et al, 2011).
Atherosclerosis analysis
For quantification of atherosclerotic lesions at aortic root,
mice were euthanized under intraperitoneal pentobarbital
anesthesia (100 mg/kg) and the hearts, including aortic root,
were fixed in 10% buffered formalin solution, followed by
paraffin embedding. A series of 5 lm sections were obtained
at the level of aortic valve and four cross sections were analy-
sed from each mouse. To quantitate lesion area and collagen
content of aortic root, the sections were stained with haemat-
oxylin and eosin, and Sirius red (Sigma, St. Louis, MO,
USA) respectively. Macrophage content of lesion at the aortic
root was studied as previously described (Ohman et al, 2008)
using immunohistochemistry with antibody to Mac-3 (1:100;
BD Biosciences, San Jose, CA, USA), although some reports
have shown that this antibody also reacts with fibroblasts
(Inoue et al, 2005). The lesion area was defined as the area
between the endothelial cell layer and internal elastic lamina.
Sirius red-positive area was expressed as percentage of the
total lesion area. All images of atherosclerotic lesions were
analysed using National Institutes of Health (NIH, Bethesda,
MD, USA) IMAGE software (ImageJ).
Carotid arterial thrombosis
To induce thrombosis, photochemical injury was performed
on carotid arteries from WT mice receiving WT or Hbbhbs/hbs
bone marrow as previously described (Eitzman et al, 2000).
Briefly, mice were anesthetized and secured in the supine
position under a dissecting microscope (Nikon SMZ-2T,
Mager Scientific, Inc., Dexter, MI, USA). The right common
carotid artery was isolated and blood flow was monitored
with a Doppler flow probe (Transonic, Ithaca, NY, USA). A
15-mW green light laser (540 nm) (Melles Griot, Carlsbad,
CA, USA) was applied to the mid common carotid artery
before injection of Rose Bengal (50 mg/kg in phosphate-buf-
fered saline; PBS) (Fisher, Fair Lawn, NJ, USA) via the tail
vein. Arterial thrombosis was defined as flow cessation for at
least 10 min. Flow in the carotid artery was monitored for
90 min.
Leucocyte infusion
Leucocytes were isolated from whole blood obtained from
WT mice that had been transplanted with either WT or
Hbbhbs/hbs bone marrow using ACK lysis buffer (Lanza Inc.,
Walkersville, MD, USA). 10-week-old WT mice were used as
recipients for leucocyte infusion. Each recipient mouse was
injected with 05 9 106 leucocytes via the tail vein. Following
leucocyte infusion, the carotid arterial thrombosis study was
performed as described above.
Real-Time Polymerase Chain Reaction (RT-PCR)
RNA from frozen liver (20 mg) was isolated using a QIAGEN
RNeasy Mini Kit (QIAGEN Inc., Valencia, CA, USA). The
primer sets for specific amplification of heme oxygenase-1
(HMOX1) and GAPDH were purchased from Applied Biosys-
tems (Carlsbad, CA, USA). RT-PCR was performed using an
ABI Prism 7000 Sequence Detection System (Applied Biosys-
tems, Carlsbad, CA). 100 ng of RNA and 1 ll of primer were
used per reaction. 7000 System SDS Software and the 2-DDCT
Atherosclerosis and Thrombosis in Sickle Cell Disease
ª 2013 John Wiley & Sons Ltd 121
British Journal of Haematology, 2013, 162, 120–129
method (Livak & Schmittgen, 2001) were used to analyse the
results. Results were presented as fold change of transcripts for
target normalized to internal control (GAPDH).
HMOX1 inhibition
A specific HMOX1 inhibitor, zinc protoporphyrin IX (ZnP-
PIX, Sigma, St. Louis, MO, USA), was prepared in 01 N
NaOH, and then titrated to pH 74 using 01 N HCl. At
14 weeks of age (6 weeks after BMT), ZnPPIX (5 mg/kg in
09% NaCl) was given to BMT Apoe/, Hbbhbs/hbs mice
intraperitoneally twice a week for 14 weeks. Control BMT
Apoe/, Hbbhbs/hbs mice received vehicle control.
For thrombosis studies, ZnPPIX (25 mg/kg) was injected
intraperitoneally to BMT Hbbhbs/hbs mice for total of two
doses every other day. Control BMT Hbbhbs/hbs mice received
vehicle control.
Heme oxygenase activity assay
The enzyme activity of heme oxygenase (HMOX) was mea-
sured as previously described (Motterlini et al, 1995). Briefly,
50 mg frozen liver tissue was homogenized in 250 ll PBS,
and centrifuged at 18 000 g for 10 min at 4°C. The source of
biliverdin reductase for the assay was liver cytosol prepared
from the 105 000 g supernatant fraction of 2 mg homoge-
nized WT liver tissue. To initiate the reaction, 200 ll super-
natant of liver sample was added to reaction system
containing 08 mmol/l NADPH, 2 mmol/l glucose-6-phos-
phate, 02 units glucose-6-phosphate dehydrogenase,
02 mmol/l MgCl2, 002 mmol/l haemin, and 200 ll liver
cytosol in a final volume of 300 ll. The reaction occurred for
1 h in the dark at 37°C and was then stopped by mixing 1:1
with chloroform. The extracted bilirubin in the chloroform
layer was measured at 464 nm subtracted by background
absorption at 530 nm. The HMOX activity was expressed as
formation of bilirubin (pmol) per milligram of sample in 1 h.
Plasma measurements
Plasma samples were collected via ventricular puncture at the
time of euthanasia. Circulating levels of HMOX1 were mea-
sured with a commercially available murine enzyme-linked
immunsorbent assay kit (Clontech Laboratories, Inc., Moun-
tain View, CA, USA) according to the manufacturer’s
instructions. Lipids were measured in the Chemistry Core of
the Michigan Diabetes Research and Training Center using
Enzymatic-Colorimetric, HDL-Direct, or Equal Diagnostics
kits (Roche, Indianapolis, IN, USA).
Statistical analysis
All data are presented as mean  standard error. Statistical
analysis was carried out using GraphPad Prism. Results
were analysed using unpaired t-test for comparison between
two groups. For multiple comparisons, results were analy-
sed using one-way ANOVA followed by Tukey post-test
analysis. Probability values <005 were considered statisti-
cally significant.
Results
Characteristics of BMT sickle mice
Mice receiving Hbbhbs/hbs BMT were anaemic and displayed
reticulocytosis and splenomegaly compared to mice receiving
WT BMT, indicating the BMT was successful in producing a
model of SCD (Table I). Human sickle haemoglobin content
was 898  08% in Apoe/ SCD mice (n = 9), similar to
previous reports of SCD mice without BMT (Ryan et al, 1997;
Campbell et al, 2011). Spleen weights were greater in Apoe/
recipients compared to Apoe+/+ recipients and were markedly
increased in Apoe/ SCD mice compared to Apoe+/+ SCD
mice. The increased spleen size correlated with increased retic-
ulocytosis in the Apoe/ SCD mice with a trend towards more
severe anaemia (Table I). White blood cell counts were signifi-
cantly increased in Apoe/ SCD mice compared with Apoe/
control and Apoe+/+SCD mice (Table I).
Effect of SCD on atherosclerosis and lipids
To study the effect of SCD on atherosclerosis, Apoe/ chi-
meric mice with either Hbbhbs/hbs or WT bone marrow on a
Western diet were analysed. Atherosclerotic lesion area
involving the aortic root was significantly reduced in Apoe/
SCD mice compared with Apoe/ control mice (Fig 1A-C).
Reduced lesion area in Apoe/ SCD mice was associated
with reduced macrophage content of atherosclerotic plaques,
as demonstrated by reduced immunostaining for Mac-3
(Fig 1D-F) along with increased collagen content as deter-
mined by Sirius red staining (Fig 1G-I). Atherosclerotic
lesions involving the carotid arteries were not observed in
either group at this age in this model. Cholesterol levels were
reduced in Apoe/ SCD mice compared to Apoe/ control
mice (Table II). In particular, low-density lipoprotein (LDL)
levels were lower in Apoe/ SCD mice while high-density
lipoprotein (HDL) and triglyceride levels were not signifi-
cantly different (Table II).
Effect of SCD on carotid arterial thrombosis
To determine if carotid thrombosis following endothelial
injury was affected in SCD mice, WT or SCD mice were sub-
jected to photochemical injury at the mid common carotid
artery with rose bengal. Time to thrombosis was prolonged
in SCD mice compared to WT mice (Fig 2), indicating that
SCD confers protection against arterial thrombosis in this
model. As leucocytes have been shown to be a potential
source of HMOX1 in SCD (Jison et al, 2004), we infused
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leucocytes isolated from either SCD or WT mice and deter-
mined the time to thrombosis in WT mice. Consistent with
a vasculo-protective effect of SCD leucocytes, WT mice that
received infusion of SCD leucocytes exhibited prolonged time
to thrombosis compared to WT mice that received WT leu-
cocytes (Fig 3).
Effect of HMOX1 inhibition on atherosclerosis and
thrombosis in SCD mice
To specifically address the role of HMOX1 towards protec-
tion from atherosclerosis and thrombosis in SCD mice, we
first measured expression and activity of HMOX1. HMOX
Table I. Characteristics of BMT SCD mice.
Apoe/ Apoe/ SCD WT SCD
Body weight (g) 292  16 293  05 254  06* 248  02**
Spleen weight (mg) 1575  136 6542  392† 715  0002* 3561  001**,†
Reticulocyte (%) 69  07 317  11† 304  08* 194  12**,†
Haemoglobin (g/l) 125  50 92  60‡ 117  20 96  40†
Haematocrit (%) 371  15 267  19† 356  06 291  17‡
WBC (x 109/l) 95  12 248  29‡ 101  13 139  12**
Platelets (x 109/l) 7320  1005 7280  770 8556  1045 7175  328
SCD, sickle cell disease; WT, wild-type; WBC, white blood cells.
*P < 005 compared with Apoe/ or Apoe/ SCD.
†P < 001 compared with corresponding control.
‡P < 005 compared with corresponding control.
**P < 001 compared with Apoe/ or Apoe/ SCD.
(A) (B) (C)
(D) (E) (F)
(G) (H) (I)
Fig 1. Effect of SCD on atherosclerosis in Apoe/ mice. A, B: Representative photomicrographs of aortic lesions in (A) Apoe/ control (n = 7)
and (B) Apoe/ sickle cell disease (SCD) mice (n = 9). C: Quantification of lesion area at aortic root. D, E: Representative photomicrographs of
Mac3 staining of aortic lesion in (D) Apoe/ control and (E) Apoe/ SCD mice. F: Quantification of Mac3 positive area in aortic lesions. G, H:
Representative photomicrographs of Sirius red staining of aortic lesion in (G) Apoe/ control and (H) Apoe/ SCD mice. I: Quantification of
the ratio of Sirius red positive area over lesion area in aortic lesions. Scale bar: 50 lm. *P < 001.
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activity (Fig 4A) and HMOX1 expression (Fig 4B) in the
liver were both increased in SCD mice compared to control
mice. Circulating levels of HMOX1 were also significantly
higher in SCD mice compared with control mice (Fig 4C).
To determine the causal role of HMOX1 in mediating vas-
cular protection in SCD mice, a specific inhibitor of HMOX1
activity, ZnPPIX, was administered to SCD mice. Following
treatment, HMOX activity was inhibited by ZnPPIX in livers
of SCD mice compared with saline-injected control SCD
mice (Fig 4A). Hmox1 mRNA expression levels of in ZnP-
PIX-injected SCD mice were similar compared to those in
saline-injected control SCD mice (Fig 4B). Circulating levels
of HMOX1 were significantly increased after inhibition in
WT control mice, but not in SCD mice (Fig 4C).
Following ZnPPIX treatment of Apoe/ SCD mice, the ath-
erosclerotic lesion area involving the aortic root was compared
to lesion areas in saline-injected Apoe/ SCD mice. The lesion
area was significantly increased after chronic inhibition of
HMOX1 in Apoe/ SCD mice (Fig 5A-C). The collagen con-
tent of aortic atherosclerotic lesions was significantly decreased
after HMOX1 inhibition in Apoe/ SCD mice compared with
saline-injected SCD mice (Fig 5D-F). Cholesterol levels were
not affected in Apoe/ SCD mice by HMOX1 inhibition com-
pared with saline-injected Apoe/ SCD mice (37  03 vs.
41  03 mmol/l, n = 5 per group). Similarly, HMOX1 inhi-
bition had no significant effect on LDL levels compared with
saline-injected Apoe/ SCD mice (07  01 vs. 08  01
mmol/l, n = 5 per group). Splenomegaly was not affected by
HMOX1 inhibition in Apoe/ SCD mice compared with
saline-injected Apoe/ SCD mice (4646  449 vs. 4889 
450 mg, n = 5 per group). To determine if HMOX1 was
involved in the protective effect of SCD on carotid artery
thrombosis, SCD mice were treated with ZnPPIX for 3 d prior
to thrombosis studies. Thrombosis times in ZnPPIX-treated
SCD mice were significantly reduced compared to times from
vehicle-injected control SCD mice (Fig 6).
Discussion
Sickle cell disease is characterized by rigid sickled erythro-
cytes that undergo premature destruction, resulting in
haemolytic anaemia and microvascular occlusions (Rees et al,
2010). In addition to long term consequences of severe anae-
mia, multiple vascular complications are associated with SCD
(Platt et al, 1991). The vascular complications associated
with SCD are complex and diverse with variable incidence
rate: pulmonary hypertension (105%) (Mehari et al, 2012),
left ventricular dysfunction (50%) (Anthi et al, 2007), dys-
rhythmia during crisis (80%) (Maisel et al, 1983) and sudden
death (40%) (Manci et al, 2003). Pathophysiological studies
have shown that sickling of erythrocytes in capillaries and
small blood vessels lead to vaso-occlusion in multiple organs
including lung, spleen, and brain (Elsharawy et al, 2009).
Stroke is considered one of the most common vascular com-
plications in patients with SCD, occurring in 24% of individ-
uals by 45 years of age (Rothman et al, 1986; Platt et al,
1991). In addition to erythrocyte-mediated microvascular
occlusions, activation of endothelial cells, platelets, coagula-
tion factors, inflammatory cytokines and leucocytes have
been shown to occur in SCD (Rees et al, 2010; De Franceschi
et al, 2011). Increased blood flow velocity measured by trans-
cranial Doppler has also been shown to be a risk factor for
stroke in SCD (Adams et al, 1997). However, the mecha-
nisms responsible for macrovascular events in SCD are
largely unknown, although both protective and deleterious
effects of SCD towards the vasculature have been described
(Kato et al, 2007; Rees et al, 2010).
Fig 2. Effect of SCD on carotid thrombosis. Time to occlusive caro-
tid thrombosis in WT mice (n = 9) and SCD mice (n = 9).
*P < 001. WT, wild type; SCD, sickle cell disease.
Table II. Lipid profile of Apoe/ SCD mice.
Apoe/ Apoe/ SCD
Cholesterol (mmol/l) 49  04 29  01*
Triglyceride (mmol/l) 11  02 12  02
HDL (mmol/l) 08  01 06  01
LDL (mmol/l) 16  01 06  01†
*P < 005 compared with Apoe/ control.
†P < 001 compared with Apoe/ control.
Fig 3. Effect of leucocyte infusion on carotid thrombosis. Time to
occlusive carotid thrombosis in WT mice (n = 9) infused with WT
leucocytes and WT mice (n = 9) infused with SCD leucocytes.
*P < 005. WT, wild type; SCD, sickle cell disease.
H. Wang et al
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Atherosclerosis is the most common underlying substrate
for stroke in the general population (Viles-Gonzalez et al,
2004). Early events in atherosclerosis involve lipid and mac-
rophage influx into the subendothelial space of arteries
(Ross, 1995). Even though stroke occurs even in very young
patients with SCD, the pathophysiological events observed in
early atherosclerosis could be similarly involved in SCD as
increases in markers and mediators of atherosclerosis, such
as soluble vascular cell adhesion molecule 1, intercellular
adhesion molecule, E-selectin, P-selectin, C-reactive protein,
tumour necrosis factor-a, tissue factor and leucocyte activa-
tion, have been described in patients with SCD (Kato &
(A) (B)
(C)
Fig 4. Expression and activity of heme oxygen-
ase (HMOX) and effect of HMOX1 inhibition
by ZnPPIX. A: Activity of HMOX in liver from
WT (n = 6) and SCD mice (n = 5) with or
without HMOX1 inhibition. B: Expression
levels of Hmox1 transcript in liver from WT
and SCD mice with or without HMOX1
inhibition. C: Plasma HMOX1 levels in WT and
SCD mice with or without HMOX1 inhibition.
*P < 001. **P < 005. WT, wild type; SCD,
sickle cell disease.
(A) (B) (C)
(D) (E) (F)
Fig 5. Effect of ZnPPIX on atherosclerosis in SCD mice. A, B: Representative photomicrographs of aortic lesions in saline-injected (n = 5) (A)
and ZnPPIX-injected (n = 5) (B) Apoe/ SCD mice. C: Quantification of lesion area at aortic root in Apoe/ SCD mice after saline or ZnPPIX
injection. D, E: Representative photomicrographs of Sirius red staining of aortic lesion in vehicle-injected (D) and ZnPPIX-injected (E) Apoe/
SCD mice. F: Quantification of Sirius red positive in aortic lesions from Apoe/ SCD mice after saline or ZnPPIX injection. Scale bar: 50 lm.
*P < 001. **P < 005. SCD, sickle cell disease.
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Gladwin, 2008; Hoppe et al, 2011). This would be important
to know because therapies useful for patients with atheroscle-
rosis may be of benefit to patients with SCD.
To determine the effect of SCD on atherosclerosis, we
used a mouse model of atherosclerosis and generated super-
imposed SCD by transplanting bone marrow from SCD
mice. Because of the complex genetics (both strain-related
background and induced mutations), the BMT approach was
more efficient than crossing the different mutant strains.
Drawbacks of the BMT approach include the irradiation
required for the transplant procedure, which may affect
vascular endpoints, and the presence of apolipoprotein E
(APOE) in the donor marrow, which also affects atheroscle-
rosis (Boisvert et al, 1995; Linton et al, 1995). Despite these
caveats, the mice still developed sufficient atherosclerosis for
quantitation and therefore constituted a reasonable model to
address the effect of SCD on atherosclerosis. For these exper-
iments, mice were placed on a Western diet following the
BMT to accelerate the formation of atherosclerotic lesions.
Apoe/ SCD mice developed anaemia, reticulocytosis and
marked splenomegaly compared to Apoe/ control mice. Of
considerable interest, anaemia, splenomegaly and reticulocy-
tosis were also greater in the Apoe/ SCD mice compared
to the Apoe+/+ SCD mice, indicating that either hypercho-
lesterolaemia or some other function of non-haematopoietic
apolipoprotein E status may affect haemolytic anaemia in
SCD. Apoe/ mice have previously been reported to have
larger spleens than Apoe+/+ mice, however this difference was
greatly exaggerated in the setting of SCD. It could be that
splenic apoptosis is deficient in Apoe/ mice (Wang et al,
2012) and that this effect is exaggerated in the setting of a
chronic haemolytic anaemic state. The degree to which defec-
tive splenic apoptosis versus splenic hypertrophy due to
hyperlipidemia-related increased haemolysis accounts for
splenomegaly is not clear from this study. APOE has also
been shown to regulate leucocytosis (Murphy et al, 2011)
and Apoe/ SCD mice displayed exaggerated leucocytosis,
which is particularly interesting because these findings sug-
gest a synergistic effect of non-haematopoietic apolipoprotein
E with SCD on leucocytosis.
Cholesterol and LDL levels were lower in Apoe/ SCD
mice compared to Apoe/ control mice while no differences
were observed in body weight. This indicates that despite
similar dietary intake, SCD has an effect on lipid metabolism.
These results are consistent with previous reports that choles-
terol and LDL levels are lower in SCD patients (Oztas et al,
2012). The effect of SCD on lipid metabolism may be due to
increased erythropoietic activity or a consequence of the
haemolytic anaemia in SCD (Zorca et al, 2010; Oztas
et al, 2012).
Contrary to our hypotheses that SCD would accelerate ath-
erosclerosis, Apoe/ SCD mice developed less atherosclerosis
compared to Apoe/ control mice. This could be due to the
reduced LDL or to another vasculo-protective effect of SCD.
Other potential vasculo-protective mechanisms in SCD
include upregulation of HMOX1. HMOX1 is the inducible
rate-limiting enzyme involved in haem catabolism (Paine et al,
2010). It is a cytoprotective enzyme, degrading the oxidant
haem into equimolar amounts of carbon monoxide, biliverdin,
and ferrous iron (Durante, 2010). The protective effect of
HMOX1 and its products are mediated by regulation of oxida-
tive stress/mediators, such as nuclear factor kappaB (NFKB1),
activating protein (AP-1), c-Jun-NH2-terminal kinase (JNK;
MAPK8), or mitogen-activated protein kinase (MAPK1)
(Tongers et al, 2004; Kim et al, 2006; Jadhav & Ndisang,
2009). HMOX1 has previously been shown to be upregulated
in SCD and defective induction of HMOX1 may play a causal
role in some inflammatory endpoints (Hanson et al, 2011).
This is a promising candidate for protection in these models
given that induction of HMOX1 is protective against develop-
ment of vascular diseases, including endothelial dysfunction,
atherosclerosis, and thrombosis (Juan et al, 2001; Durante,
2010). Haemin induction of HMOX1 has also been shown to
be protective against vascular disease in preclinical studies
(Ishikawa et al, 2001; Liu et al, 2002; Li et al, 2011). Consis-
tent with other studies of SCD (Belcher et al, 2006), we found
that HMOX activity and levels were increased in SCD mice.
The mechanism by which HMOX1 is induced is presumably
due to haemolysis/haem products; however, we cannot exclude
other factors.
To determine the causal role of HMOX activity in
contributing to the protective role of SCD on atherosclerosis,
mice were treated chronically with ZnPPIX. Similar to previ-
ous studies (Yamashita et al, 2006), treatment with ZnPPIX
reduced HMOX activity while increasing HMOX1 protein
levels (Labbe et al, 1999). This intervention has been previ-
ously shown to also inhibit HMOX activity in SCD mice and
worsen inflammation in the lung (Belcher et al, 2006). In the
Fig 6. Effect of SCD and HMOX1 inhibition on carotid thrombosis.
Time to occlusive carotid thrombosis in SCD mice with vehicle
injection (SCD+vehicle) (n = 9), WT mice with ZnPPIX injection
(WT+ZnPPIX) (n = 3), and SCD mice with ZnPPIX injection
(SCD+ZnPPIX) (n = 3). *P < 001. **P < 005. WT, wild type;
SCD, sickle cell disease.
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current study, reduction in HMOX activity reversed some,
but not all, of the atheroprotection observed in SCD mice.
This indicates that HMOX1 upregulation in SCD contributes
to atheroprotection. This effect was not related to changes in
cholesterol because ZnPPIX treatment did not increase the
levels of cholesterol or LDL. The incomplete reversal of pro-
tection could be due to incomplete inhibition of HMOX1or
to additional protective mechanisms, such as the SCD-
induced cholesterol lowering. A particularly striking differ-
ence noted in the composition of atherosclerotic plaques
between the groups was the fibrotic nature, as evidenced by
collagen and lack of foam cells, in the SCD-related lesions.
As previously suggested (Kato & Gladwin, 2008), it is possi-
ble that a low-LDL profibrotic response in SCD mice could
lead to enhanced vascular proliferative lesions. These may be
particularly relevant at other vascular sites, such as pulmo-
nary and cerebral vasculature, where complications are rela-
tively common in SCD patients.
Given that an arterial prothrombotic state could also con-
tribute to vascular complications of SCD, we studied this
murine model of SCD in a photochemical thrombosis model.
Previous studies that have demonstrated that SCD is associ-
ated with multiple perturbations that would be expected to
enhance arterial thrombosis, including increase in coagula-
tion-related factors (Rees et al, 2010), platelet activation and
aggregation (Ataga & Orringer, 2003), impaired nitric oxide
activity (Villagra et al, 2007), and endothelial inflammation
(Ataga et al, 2008). However, as in the case with the athero-
sclerosis endpoint, SCD mice exhibited prolongation in the
time to thrombosis following carotid injury. In this model,
time to thrombosis was shown to be sensitive to alteration in
coagulation factors, platelets, and endothelial function
(Westrick et al, 2007). The mechanism by which SCD pro-
tects against early occlusive thrombus formation is unclear
but could also be related to HMOX1, because deficiency of
HMOX1 is prothrombotic in this model (Johns et al, 2009;
Fei et al, 2012) while overexpression of HMOX1 is protective
against thrombosis (Lindenblatt et al, 2004). As HMOX1 has
been shown to be upregulated in SCD leucocytes and pro-
posed to mediate a compensatory response to repetitive vas-
cular injury in SCD (Jison et al, 2004), we tested the effect
of SCD or WT leucocyte infusions into recipient WT mice.
Remarkably, acute infusion of leucocytes from SCD mice was
sufficient to prolong the time to thrombosis in WT mice,
implicating leucocytes as possible mediators of the SCD pro-
tective effect.
To determine if HMOX1 was specifically responsible for
the protection of SCD against thrombosis in this model,
mice were treated with ZnPPIX. This treatment attenuated
the protective effect of SCD on thrombosis, suggesting that
HMOX1 upregulation is mediating protection in SCD.
While these studies were originally intended to study
adverse macrovascular effects of SCD, they may provide
unique insight into vascular disease associated with SCD.
Paradoxically, we found that SCD mice are actually protected
in models of atherosclerosis and thrombosis. It may be that
protective mechanisms against vascular disease are upregulat-
ed in patients with SCD and that deficient upregulation of
these protective responses lead to vascular events. Studies in
humans with SCD vascular complications will be necessary
to test this hypothesis in regards to HMOX1. If this is the
case, then targeted therapies designed to enhance HMOX1
activity in SCD patients identified to be at risk of macrovas-
cular complications could be beneficial. Additionally, the
vasculoprotective findings in this study could have potential
therapeutic applications to the non-SCD population at risk
of vascular disease.
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